Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.56 |
| ▸ | NPC1 | O15118 | 1/20 | 0.56 |
| ▸ | GRIN1 | Q05586 | 3/20 | 0.50 |
| ▸ | GRIN2B | Q13224 | 3/20 | 0.50 |
| ▸ | THRB | P10828 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | APP | P05067 | 1/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.46 |
| ▸ | HTR1A | P08908 | 2/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30381638 | 1.00 | MEN1 (0.56) | MEN1KMT2ANPC1GRIN1GRIN2B | |
| SCHEMBL30381107 | 0.93 | MEN1 (0.56) | MEN1KMT2ANPC1GRIN1GRIN2B | |
| SCHEMBL24077252 | 0.93 | MEN1 (0.56) | MEN1KMT2ANPC1GRIN1GRIN2B | |
| SCHEMBL24077240 | 0.90 | GRIN1 (0.48) | MEN1KMT2ANPC1GRIN1GRIN2B | |
| SCHEMBL24076669 | 0.89 | SLC6A2 (0.51) | MEN1KMT2ANPC1GRIN1GRIN2B | |
| SCHEMBL24076613 | 0.88 | THRB (0.58) | MEN1KMT2AGRIN1GRIN2BTHRB | |
| SCHEMBL24077242 | 0.86 | GRIN2B (0.60) | MEN1KMT2AGRIN1GRIN2BTHRB | |
| SCHEMBL24077250 | 0.86 | GRIN1 (0.53) | MEN1KMT2AGRIN1GRIN2BTHRB | |
| SCHEMBL30381318 | 0.86 | GRIN1 (0.53) | MEN1KMT2AGRIN1GRIN2BTHRB | |
| SCHEMBL24076660 | 0.83 | GRIN1 (0.58) | MEN1KMT2ANPC1GRIN1GRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116057053-A | 5-membered heteroaryl derivatives containing at least one N and pharmaceutical compositions containing the same as active ingredient for preventing or treating mental disorders | 大邱庆北尖端医疗产业振兴财团 | 2023-05-02 | — | — | CN | claimed |
| US-20230212144-A1 | 5-MEMBERED HETEROARYL DERIVATIVE CONTAINING AT LEAST ONE N, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING MENTAL DISORDERS, CONTAINING SAME AS ACTIVE INGREDIENT | TRINEURO (KR) | 2023-07-06 | — | — | US | disclosed |
| CN-116057053-A | 5-membered heteroaryl derivatives containing at least one N and pharmaceutical compositions containing the same as active ingredient for preventing or treating mental disorders | 大邱庆北尖端医疗产业振兴财团 | 2023-05-02 | — | — | CN | disclosed |
| WO-2021241982-A1 | 5-MEMBERED HETEROARYL DERIVATIVE CONTAINING AT LEAST ONE N, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING MENTAL DISORDERS, CONTAINING SAME AS ACTIVE INGREDIENT | 재단법인 대구경북첨단의료산업진흥재단 | 2021-12-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230212144-A1 | 5-MEMBERED HETEROARYL DERIVATIVE CONTAINING AT LEAST ONE N, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING MENTAL DISORDERS, CONTAINING SAME AS ACTIVE INGREDIENT | HTR5A, HTR2C, TPH1 | MEN1 2231/4885KMT2A 2075/4885NPC1 570/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.